Cognitive Screening within Advanced Pharmaceutical Care in Elderly Patients with Suspected Metabolic Syndrome
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00077731" target="_blank" >RIV/00159816:_____/22:00077731 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064203:_____/22:10451361 RIV/00216208:11130/22:10451361
Výsledek na webu
<a href="https://www.airitilibrary.com/Publication/alDetailedMesh?DocID=P20190312001-202210-202210140002-202210140002-355-360" target="_blank" >https://www.airitilibrary.com/Publication/alDetailedMesh?DocID=P20190312001-202210-202210140002-202210140002-355-360</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.6890/IJGE.202210_16(4).0008" target="_blank" >10.6890/IJGE.202210_16(4).0008</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Cognitive Screening within Advanced Pharmaceutical Care in Elderly Patients with Suspected Metabolic Syndrome
Popis výsledku v původním jazyce
Background: Cognitive screening by pharmacists may help to identify seniors with metabolic syndrome (MetS)-related cognitive impairment. We aimed to evaluate the implementation of an easy-to-use cognitive screening into the pharmaceutical care of seniors and to test whether cognitive decline is associated with suspected MetS (sMetS).Methods: Questionnaires were completed by 323 randomly selected elderly patients receiving pharmaceutical care in community pharmacies or in senior care centres in Slovakia. The presence of sMetS was estimated according to criteria of the International Diabetes Federation. Cognitive performance was evaluated by the Montreal Cognitive Assessment (MoCA) test and its short form (s-MoCA). In these tests, the cut-offs for impaired cognitive status were <= 24, and <= 12, respectively.Results: 56% of participants scored below the screening cut-off MoCA threshold. Cognitive impairment was significantly more frequent in sMetS+ subjects (71%) vs. sMetS- (52%; p < 0.05). MoCA scores were significantly lower in sMetS+ (mean +/- SD = 20.0 +/- 5.9 points) vs. sMetS- (22.2 +/- 5.4 points; p < 0.05). sMetS components type 2 diabetes mellitus, hypertension and obesity, but not dyslipidaemia, had an influence on lower cognitive performance.Conclusions: We unveiled a significant relationship of cognitive dysfunction to sMetS in elderly patients. A quick and simple cognitive assessment could be a helpful extension of pharmaceutical care.
Název v anglickém jazyce
Cognitive Screening within Advanced Pharmaceutical Care in Elderly Patients with Suspected Metabolic Syndrome
Popis výsledku anglicky
Background: Cognitive screening by pharmacists may help to identify seniors with metabolic syndrome (MetS)-related cognitive impairment. We aimed to evaluate the implementation of an easy-to-use cognitive screening into the pharmaceutical care of seniors and to test whether cognitive decline is associated with suspected MetS (sMetS).Methods: Questionnaires were completed by 323 randomly selected elderly patients receiving pharmaceutical care in community pharmacies or in senior care centres in Slovakia. The presence of sMetS was estimated according to criteria of the International Diabetes Federation. Cognitive performance was evaluated by the Montreal Cognitive Assessment (MoCA) test and its short form (s-MoCA). In these tests, the cut-offs for impaired cognitive status were <= 24, and <= 12, respectively.Results: 56% of participants scored below the screening cut-off MoCA threshold. Cognitive impairment was significantly more frequent in sMetS+ subjects (71%) vs. sMetS- (52%; p < 0.05). MoCA scores were significantly lower in sMetS+ (mean +/- SD = 20.0 +/- 5.9 points) vs. sMetS- (22.2 +/- 5.4 points; p < 0.05). sMetS components type 2 diabetes mellitus, hypertension and obesity, but not dyslipidaemia, had an influence on lower cognitive performance.Conclusions: We unveiled a significant relationship of cognitive dysfunction to sMetS in elderly patients. A quick and simple cognitive assessment could be a helpful extension of pharmaceutical care.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30227 - Geriatrics and gerontology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
International Journal of Gerontology
ISSN
1873-9598
e-ISSN
1873-958X
Svazek periodika
16
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
TW - Čínská republika (Tchaj-wan)
Počet stran výsledku
6
Strana od-do
355-360
Kód UT WoS článku
000888027600009
EID výsledku v databázi Scopus
—